Fig. 1 · Structure
Documents & Downloads
Seletracetam lithium bromide
SV2A Modulator/Antiepileptic Agent
Seletracetam lithium bromide is a modulator of the synaptic vesicle protein SV2A, primarily investigated for its potential in the treatment of epilepsy. As an analog of the established antiepileptic agent Levetiracetam, it exhibits significant anticonvulsant activity, making it a valuable tool for research on seizure pathways and related neurological disorders. Its unique mechanism of action provides insights into synaptic transmission and may facilitate the development of novel therapeutic interventions for epilepsy.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Modulator |
| CAS Number | 2024584-38-9 |
| Applications | SV2A Modulator/Antiepileptic Agent |
| Formula | C10H14F2N2O2.1/2BrLi |
| Molecular Weight | 275.74 |
| Synonyms | Ucb 44212 lithium bromide |
| SMILES | Br[Li].NC([C@@H](N1C(C[C@H](C1)/C=C(F)\F)=O)CC)=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.